Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.

Next Previous
Trial Profile

A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary) ; Cannabinoids
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Therapeutic Use
  • Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

  • 13 Nov 2020 Results from an analysis of three Phase 3 clinical trials of nabiximols(GWMS0106, GWSP0604, and SAVANT) published in the Greenwich Biosciences Media Release.
  • 13 Nov 2020 According to a Greenwich Biosciences media release, data from an analysis of three Phase 3 clinical trials of nabiximols(GWMS0106, GWSP0604, and SAVANT) will be presented at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Virtual Annual Assembly. The research will be presented live during the November 14 Research Spotlight session on Neurological Rehabilitation.
  • 01 May 2020 Results assessing the relationship between spasticity and muscle strength in lower extremities or mobility, using data from 3 RCTs (GWMS0106, GWSP0604, and SAVANT) presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top